This is a vaccine treatment design based on specific CTLs against EML4-ALK positive cancer cells, and further research and analysis are still required in order to realize the application of this type of vaccine in ALK positive NSCLC patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.